

NEW

Victoza® demonstrated
CV risk reduction in
the **LEADER** trial.¹

Reference:

1. Marso SP, et al; Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. June 13, 2016.



ViCTOZA®
liraglutide